EMYRIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.052 AUD | +1.96% |
|
-3.70% | 0.00% |
| 23/04 | Emyria to Raise AU$2.3 Million via Placement | MT |
| 10/04 | Emyria Launches Empax Center | MT |
| Sales 2022 | 1.82 2.8 152.1 | Sales 2023 | 1.59 2.45 132.91 | Capitalization | 38.54M 59.29M 3.22B |
|---|---|---|---|---|---|
| Net income 2022 | -7M -10.77M -584M | Net income 2023 | -5M -7.69M -417M | EV / Sales 2022 | 2,68,89,502 x |
| Net cash position 2022 | 3.25M 4.99M 271M | Net cash position 2023 | 1.46M 2.25M 122M | EV / Sales 2023 | 2,32,85,243 x |
| P/E ratio 2022 |
-6.91
x | P/E ratio 2023 |
-6.98
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.96% | ||
| 1 week | -3.70% | ||
| Current month | -11.86% | ||
| 1 month | -11.86% | ||
| 3 months | +1.96% | ||
| 6 months | -23.53% |
1 week
0.05
0.05
1 month
0.050.07
Current year
0.040.08
1 year
0.040.18
3 years
0.040.51
5 years
0.040.51
10 years
0.040.51
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Winlo
CEO | Chief Executive Officer | - | 03/19/03 |
Joseph Ohayon
DFI | Director of Finance/CFO | - | - |
Mary Ann Rennie
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mohit Kaushal
BRD | Director/Board Member | 45 | 21/23/21 |
John Tooke
BRD | Director/Board Member | 75 | 23/18/23 |
Karen Smith
BRD | Director/Board Member | 56 | 29/21/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 0.052 | +1.96% | 169 424 |
| 30/24/30 | 0.051 | 0.00% | 136,487 |
| 29/24/29 | 0.051 | +4.08% | 178,126 |
| 26/24/26 | 0.049 | -3.92% | 234,799 |
| 24/24/24 | 0.051 | -5.56% | 529,273 |
Delayed Quote Australian S.E., May 01, 2024 at 11:40 am IST
More quotes
Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 12.14M | |
| -18.46% | 16.57B | |
| +4.50% | 12.4B | |
| +4.98% | 11.69B | |
| +4.26% | 10.24B | |
| -2.91% | 7.76B | |
| +20.21% | 7.17B | |
| +6.83% | 6.74B | |
| +50.68% | 4.65B | |
| -5.12% | 4.25B |
- Stock Market
- Equities
- EMD Stock
